The association of elevated circulating endocan levels with lung function decline in COPD patients

Area of Science:

• Pulmonary Medicine
• Inflammation Research
• Biomarker Discovery

Background:

• Endocan is a novel inflammatory marker implicated in various inflammatory diseases.
• Its specific role in the pathogenesis of Chronic Obstructive Pulmonary Disease (COPD) is not well-defined.
• This study investigates the potential involvement of endocan in COPD.

Purpose of the Study:

• To explore the association between circulating endocan levels and COPD.
• To determine the relationship between endocan and lung function parameters in COPD patients.
• To investigate the potential role of endocan in the pathogenesis of COPD.

Main Methods:

• Plasma endocan, Fas, and Fas ligand (Fas-L) concentrations were measured using Magnetic Luminex screening assays in 27 healthy volunteers, 55 COPD patients, and 36 AECOPD patients.
• Statistical analyses included independent t-tests, chi-squared tests, and Wilcoxon rank sum tests for group comparisons.
• Pearson's partial correlation and multiple linear regression were used to analyze correlations between plasma endocan, lung function, Fas, and Fas-L, adjusted for covariates.

Main Results:

• Plasma endocan levels were significantly higher in COPD patients (509.7±18.25 pg/mL) and AECOPD patients (524.7±27.18 pg/mL) compared to healthy volunteers (434.8±18.98 pg/mL).
• Circulating endocan showed a negative correlation with FEV1/FVC, FEV1/predictive, and FVC.
• A positive correlation was observed between endocan and Fas levels.

Conclusions:

• Elevated circulating endocan levels are associated with impaired lung ventilation function in COPD and AECOPD.
• Endocan may play a role in the pathogenesis of COPD, potentially through influencing apoptosis.
• Endocan represents a potential biomarker for COPD severity and progression.